←
Greenstone Biosciences275 posts
Greenstone Biosciences avatar

Greenstone Biosciences

@GreenstoneBio

Transforming #drugdiscovery through #genomics #stemcells #AI/ML. Stanford Research Park. Visit: greenstonebio.com

◷ Joined February 2022▧ 76 Photos and videos
Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·19 Feb 2025

To support the important work happening in academic research labs around the world, we continue to offer complimentary human induced pluripotent stem cell (hiPSC) lines (processing and shipping not included) to academic researchers. Details below ⬇️

Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Nov 13

In Stem Cell Research, researchers from Stanford University and Greenstone Biosciences report two patient-derived iPSC lines carrying distinct LMNA mutations associated with EDMD. Read more about this here: lnkd.in/p/gSDZRCkk

Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Nov 6

Congratulations to Greenstone Biosciences scientist Ibrahim M. Sayed and co-authors Mey-Sam Chörsi, Stephen N. Jones, Zhenan Bao, and Greenstone Co-Founder Joseph C. Wu on their new Review published in Nature Materials! Read more here: lnkd.in/p/gxuJrNTp

Post attachment
Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Oct 30

Today, we are sharing a new resource for cardiovascular research. In Stem Cell Research, researchers from Stanford University report two patient-derived iPSC lines from individuals diagnosed with TTN-associated DCM. Read more here: lnkd.in/p/gCk6xK-2

Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Oct 23

New research from Stanford University and Greenstone Biosciences introduces two patient-derived iPSC lines for myotonic dystrophy type 1 (DM1), providing valuable tools to study RNA toxicity, disrupted splicing, and potential therapies. Read more here: lnkd.in/p/gi7Pst8Y

Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Aug 13

In a new article from Drug Target Review, Greenstone Biosciences co-founder Dr. @Joseph_C_Wu discusses how New Approach Methodologies (NAMs) can help close the gap between existing models and human relevance. Read the full article here: drugtargetreview.com/home/re…

Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Aug 7

Greenstone Biosciences has been awarded a Catalyze R61 grant from the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, to develop new therapeutic approaches for cardiac fibrosis and dilated cardiomyopathy in DMD Reade more here: linkedin.com/posts/greenston…

Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Jul 14

BAG3-associated cardiomyopathy can progress rapidly, but the biology remains difficult to study in conventional models. To help this research, Greenstone Biosciences is now offering 10 patient-derived iPSC lines carrying distinct BAG3 variants Read more: linkedin.com/posts/greenston…

Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Jul 8

PTEN Hamartoma Tumor Syndrome is a rare inherited condition caused by changes in the PTEN gene, and Greenstone Biosciences has contributed to a new paper published in Stem Cell Research that expands tools available to researchers studying it Read more: linkedin.com/feed/update/urn…

Greenstone Biosciences avatar
Greenstone Biosciences@GreenstoneBio·Jul 1

The @FDA's push to reduce reliance on animal testing is a call to action for platforms built to replace it. Greenstone Biosciences’ iPSC biobank includes more than 2,500 patient-derived lines of diverse ancestries, ages, and diseases. Read more here: linkedin.com/feed/update/urn…